Search Results
May 07, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on
More news about: Pomerantz LLP
May 06, 2026, 19:10 ET RGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"), of the important June 23, 2026 lead plaintiff deadline.So what:
More news about: THE ROSEN LAW FIRM, P. A.
May 06, 2026, 09:47 ET RGC DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026
national securities law firm, is investigating potential claims against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and reminds investors of the June 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
May 06, 2026, 09:00 ET Levi & Korsinsky Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC
Ranked among ISS Top 50 for seven consecutive years.Frequently Asked Questions About the RGC LawsuitQ: Who is eligible to join the RGC investor lawsuit? A: Investors who purchased RGC stock or securities between October 28, 2024 and October 31, 2025 and suffered financial losses
More news about: Levi & Korsinsky, LLP
May 05, 2026, 16:55 ET Robbins LLP Urges RGC Investors Who Lost Money Investing in Regencell Bioscience Holdings Limited to Contact the Firm for Information About Leading the Securities Class Action
stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development,
More news about: Robbins LLP
May 05, 2026, 09:00 ET RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC).
More news about: The Gross Law Firm
May 03, 2026, 08:43 ET Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models
function. In each model, tazbentetol reversed decreases in pERG amplitude (a reflection of RGC viability) and in the db/db mouse tazbentetol also shortened the latency of the pVEP (a reflection of improved RGC axon conduction). The latter effect may be attributable to both a preservation of axons and
More news about: Spinogenix
May 01, 2026, 09:39 ET RGC SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026
national securities law firm, is investigating potential claims against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and reminds investors of the June 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 30, 2026, 21:15 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is
More news about: Pomerantz LLP
Apr 29, 2026, 09:00 ET RGC LAWSUIT ALERT: Levi & Korsinsky Notifies Regencell Bioscience Holdings Limited Investors of a Class Action Lawsuit and Upcoming Deadline
& Korsinsky, LLP notifies investors in Regencell Bioscience Holdings Limited ("Regencell Bioscience Holdings Limited" or the "Company") (NASDAQ: RGC) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 27, 2026, 21:15 ET RGC Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Regencell Bioscience Holdings Limited
stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development,
More news about: Robbins LLP
Apr 04, 2026, 15:50 ET TriNetX 與 Regeneron 展開合作，獲取 3 億名患者的去識別化電子健康紀錄，以促進生命科學及數碼健康解決方案的研究與產品開發
選中，透過我們龐大的全球聯邦式學術醫療中心及其他頂尖醫療研究機構網絡，提供 TriNetX 獨一無二、既廣且深的科研級數據存取服務。」醫學博士、高級副總裁、RGC 主管兼 Regeneron Genetic Medicines 聯席主管 Aris Baras 表示：「這對 RGC 來說是重要里程碑，亦是實現我們核心使命的強大新途徑：建立全球規模最大、內容最豐富的人類健康數據庫，以推動藥物研發，並為消費者、病人及醫護人員開創數碼健康解決方案。 TriNetX 建立了全球領先的平台，在推動大規模研究方面卓越實績有目共睹。 RGC 花了十多年生成基因組及現今的蛋白質組數據，並將這些分子數據大規模地與縱向健康紀錄整合。 融合這些平台，將強大的人類健康數據庫與分析及人工智能能力集於一身，有助探索和開發針對重病的創新藥物，並創造我們期望能改變預測、預防和管理疾病能力的數碼健康解決方案。」高級副總裁兼
More news about: TriNetX, LLC.
Apr 04, 2026, 15:50 ET A TriNetX colabora com a Regeneron para acessar prontuários eletrônicos de saúde desidentificados de 300 milhões de pacientes, motivando pesquisas e desenvolvimento de produtos em ciências da vida e soluções digitais de saúde
saúde", declarou o Dr. Aris Baras, vice-presidente sênior, chefe da RGC e cochefe da Regeneron Genetic Medicines. "A TriNetX construiu uma plataforma líder mundial com um histórico comprovado de viabilização de pesquisas em larga escala. O RGC passou mais de uma década gerando dados genômicos e agora proteômicos
More news about: TriNetX, LLC.
Apr 04, 2026, 15:45 ET TriNetX colabora con Regeneron para acceder a historias clínicas electrónicas no identificables de 300 millones de pacientes, para impulsar la investigación y el desarrollo de productos en ciencias de la vida y soluciones de salud digital
Dr. Aris Baras, vicepresidente sénior, director del RGC y codirector de Regeneron Genetic Medicines. "TriNetX ha desarrollado una plataforma líder a nivel mundial con una trayectoria comprobada como facilitador de investigaciones a gran escala. El RGC ha dedicado más de una década a generar datos genómicos
More news about: TriNetX, LLC.
Apr 03, 2026, 11:47 ET TriNetX arbeitet mit Regeneron zusammen, um Zugang zu anonymisierten elektronischen Patientenakten von 300 Millionen Patienten zu erhalten und damit die Forschung und Produktentwicklung in den Bereichen Biowissenschaften und digitale Gesundheitslösungen voranzutreiben
sagte Dr. Aris Baras, Senior Vizepräsident, Leiter des RGC und Co-Leiter von Regeneron Genetic Medicines. „TriNetX hat eine weltweit führende Plattform aufgebaut, die sich bei der Ermöglichung von Forschung in großem Maßstab bewährt hat. Das RGC sammelt seit über einem Jahrzehnt Genomdaten und nun auch
More news about: TriNetX, LLC.
Apr 03, 2026, 11:32 ET 트라이넷엑스, 리제네론과 협력해 3억 명의 비식별 전자 건강 기록에 접근… 생명과학 및 디지털 헬스 솔루션 분야의 연구 및 제품 개발 추진
리제네론 유전학 센터®(RGC®)가 생성한 유전체 및 단백질체 데이터와 매칭할 수 있는 역량을 갖추게 된다. 이러한 매칭은 HIPAA와 GDPR을 포함한 모든 관련
More news about: TriNetX, LLC.
Apr 03, 2026, 09:09 ET TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados
doctor Aris Baras, vicepresidente sénior, director del RGC y codirector de Regeneron Genetic Medicines. "TriNetX ha creado una plataforma líder a nivel mundial con una trayectoria comprobada en la facilitación de la investigación a gran escala. El RGC ha dedicado más de una década a generar datos genómicos
More news about: TriNetX, LLC.
Apr 03, 2026, 09:02 ET TriNetX 、Regeneronとの提携により、3億人の患者の電子カルテにアクセスし、ライフサイエンスおよびデジタルヘルスソリューションの研究・製品開発を推進
(RGC®)が生成するゲノムおよびプロテオームデータと照合する能力を有しています。このような照合は、HIPAAおよびGDPRを含む、適用されるすべてのデータプライバシーに関する法律に従って実施されます。
More news about: TriNetX, LLC.
Apr 02, 2026, 23:56 ET TriNetX collabore avec Regeneron pour accéder aux dossiers médicaux électroniques dépersonnalisés de 300 millions de patients afin de stimuler la recherche et le développement de produits dans le domaine des sciences de la vie et des solutions de santé numérique
déclaré Aris Baras, M.D., vice-président senior, directeur de RGC et codirecteur de Regeneron Genetic Medicines. « TriNetX a créé une plateforme d'envergure mondiale qui a fait ses preuves dans le domaine de la recherche à grande échelle. Le RGC a passé plus d'une décennie à générer des données génomiques
More news about: TriNetX, LLC.
Apr 02, 2026, 16:30 ET TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head
More news about: TriNetX, LLC.
Apr 02, 2026, 16:30 ET TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head
More news about: TriNetX, LLC.
Mar 05, 2026, 09:15 ET Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
patients." RGC, a wholly owned subsidiary of Regeneron, harnesses the vast potential of human genetics to discover important new medicines, validate existing research programs, and optimize clinical trials. With a database of nearly 3 million sequenced exomes and de-identified EHRs, RGC enables meaningful
More news about: Illumina, Inc.
Jan 21, 2026, 09:08 ET Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research
No. 1834-RBPMS)—a next-generation antibody designed to deliver superior reproducibility, specificity, and performance in retinal ganglion cell (RGC) research. Developed under the PhosphoSolutions brand, the recombinant Guinea Pig RBPMS Antibody continues a legacy of high-performance neuroscience
More news about: Antibodies Inc.
Dec 03, 2025, 00:41 ET Le Royal Group célèbre le succès du concert "Rise for Khmer" et réaffirme son engagement en faveur de la culture, de l'unité et du progrès national
https://mma.prnewswire.com/media/2836031/RGC__Rise_for_Khmer__Press_Release_01.jpgPhoto -
More news about: Royal Group
Dec 02, 2025, 02:21 ET Royal Group Celebrates the Success of "Rise for Khmer" Concert, Reaffirming Its Commitment to Culture, Unity, and National Progress
https://mma.prnewswire.com/media/2836031/RGC__Rise_for_Khmer__Press_Release_01.jpgPhoto -
More news about: Royal Group